Welcome to the Working Group on New TB Drugs Blog
TB R&D Weekly Update: Tailoring TB Treatment Based on Host Genotype?
This week we have research out of the Ramakrishnan Laboratory that challenges thinking around tuberculosis treatment and considerations of host genotypes. Additional links to TB R&D news are included.
Summary Available! TB Clinical Trials Consultants Meeting
On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.
TB R&D Weekly Update: SQ109 and PNU Compounds Additive
In this week’s article, we look at two drugs in our Global TB Drug Pipeline and how they interact with each other: SQ109 (class: Ethylenediamines, Sequella) and PNU-100480 (called Sutezolid, class: Oxazolidinone, Pfizer). Additional links to TB R&D news are included.
Posted in Early Drug Development, Front Lines of TB R&D, TB News, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Dr. Yossef Av-Gay
This week we interview Dr. Yossef Av-Gay and discuss his recently published paper, his contribution to TB drug discovery and the focus of his research. Dr. Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in PNAS that provides evidence to that points to a specific protein that allows Mtb to bypass the body’s defenses. Additional TB R&D news links are included.
4th Annual G-FINDER Survey Released
Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been particularly hard hit, as eight of the top twelve public donors cut their funding in 2010. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients–donors must commit to taking them across the finish line.
TB R&D Weekly Update: Tyrosine Kinases as Therapeutic Targets against TB
This week’s article looks at host factors that contribute to the ability of Mycobacterium tuberculosis (Mtb) to enter and survive within macrophages. The authors explore the role of tyrosine kinases (TKs) as a mediator for Mtb and the use of an inhibitor of TKs to act against Mtb and related bacteria. Additional links to TB R&D news is included
Posted in Front Lines of TB R&D, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast interview with Dr. Gyanu Lamicchane
Microbial geneticist Dr. Gyanu Lamichhane of the Johns Hopkins Center for Tuberculosis Research is one of 49 recipients of the New Innovator Award, which is given to promising scientists in the early stages of their careers and is supported directly with $1.5 million in research funding over five years. In this interview, we discuss the award and the related research that lead to the award, as well as, Dr. Lamichhane’s motivation to work with TB. Additional links to TB R&D news are included.
International TB Research Roadmap Launched!
A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on Saturday at the Union World Conference on Lung Health.
TB R&D Weekly Update: Progress in Development of New TB Drugs
During last week, the Stop TB Partnership Working Group on New Drugs had a successful annual meeting in Lille, France, in conjunction with the 42nd Union World Conference. There were quite a few updates to the Global TB Drugs Pipeline showing progress toward the goal of better treatment for TB in all patient populations. Additional links to TB R&D news are included.
TB R&D Weekly Update: Podcast Interview with Dr. Sanjib Bhakta
This week’s interview is with Dr. Sanjib Bhkata who is Head of Mycobacteria Research Laboratory, Microbiology, Department of Biological Sciences, Institute of Structural and Molecular Biology at the Birbeck University of London. Dr. Bhakta’s Laboratory has developed an innovative method for screening compounds that is more efficient and just as accurate as more widely used methods. Additional links to TB R&D news are included.
-
Toppix TB News- Editorial: Lives at risk if the U.S. shortchanges Global Fund 4 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- WHO says TB in Russia displays highest known drug resistance 3 Feb 2012
- Media outlets examine Global Fund's future as it enters second decade 3 Feb 2012
